Production (Stage)
Benitec Biopharma Inc.
BNTC
$12.78
-$1.01-7.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 7.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 7.00K |
| Cost of Revenue | 0.00 | -3.00K | -2.00K | -108.00K | -108.00K |
| Gross Profit | 0.00 | 3.00K | 2.00K | 108.00K | 115.00K |
| SG&A Expenses | 11.99M | 9.36M | 7.64M | 6.99M | 6.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.14M | 24.09M | 22.41M | 22.49M | 21.50M |
| Operating Income | -30.14M | -24.09M | -22.41M | -22.49M | -21.49M |
| Income Before Tax | -26.49M | -21.42M | -20.86M | -21.75M | -21.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.49 | -21.42 | -20.86 | -21.75 | -21.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.49M | -21.42M | -20.86M | -21.75M | -21.69M |
| EBIT | -30.14M | -24.09M | -22.41M | -22.49M | -21.49M |
| EBITDA | -30.06M | -24.00M | -22.31M | -22.40M | -21.41M |
| EPS Basic | -1.65 | -1.64 | -3.95 | -6.52 | -8.75 |
| Normalized Basic EPS | -0.99 | -0.98 | -2.42 | -3.85 | -5.29 |
| EPS Diluted | -1.65 | -1.64 | -3.95 | -6.52 | -8.75 |
| Normalized Diluted EPS | -0.99 | -0.98 | -2.42 | -3.85 | -5.29 |
| Average Basic Shares Outstanding | 80.21M | 59.89M | 40.40M | 31.91M | 24.66M |
| Average Diluted Shares Outstanding | 80.21M | 59.89M | 40.40M | 31.91M | 24.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |